Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lazertinib
Pharma
J&J combo survival win signals new era in EGFR lung cancer
The J&J combo of Rybrevant and Lazcluze is expected to offer at least an extra year of life versus Tagrisso in first-line EGFR lung cancer.
Angus Liu
Mar 26, 2025 11:45am
Akeso-Summit, BIOSECURE, Candid and more—Fierce Pharma Asia
Sep 13, 2024 8:53am
J&J builds case for Tagrisso rival with survival analysis
Sep 8, 2024 2:07pm
J&J-Yuhan, Merck, biosecurity—Fierce Pharma Asia
Aug 23, 2024 10:05am
J&J's Tagrisso challenger wins FDA nod in first-line lung cancer
Aug 20, 2024 10:26am
ESMO: Should AZ worry about J&J's Tagrisso head-to-head win?
Oct 23, 2023 10:30am
